ARTICLE | Company News
Chiron, Evans Medical Ltd. infectious diseases news
January 19, 1998 8:00 AM UTC
The U.K.'s High Court of Justice ruled that the U.K. portion of Evans Medical's European Patent No. 162,639 is invalid. Evans Medical, a subsidiary of Medeva Group PLC (London, U.K.), had asserted that the '639 patent covered the p69 antigen of bordetella pertussis used in CHIR's pertussis vaccines. CHIR has completed clinical trials for its two acellular pertussis vaccines, Acelluvax, a genetically engineered acellular pertussis vaccine, and TriAcelluvax, a combination vaccine that includes diphtheria and tetanus. ...